BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• 

  Study Calls Out Lack of Reproducibility in Cancer Research

  Known as the Reproducibility Project: Cancer Biology, it spent eight years replicating experiments from high-impact cancer biology papers published between 2010 and 2012.

  December 8, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Pharm Country

  Pfizer Reassures with Booster Data After Reports of Lowered Omicron Protection

  Pfizer’s preliminary laboratory studies have shown that the third booster dose increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant.

  December 8, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Report: Biogen Eyes Massive Layoffs in Wake of Disappointing Aduhelm Rollout

  The company could lay off as many as 1,000 employees as it continues to deal with the controversial treatment.

  December 8, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Alleged Sabatini Sexual Harassment Victim Files Countersuit

  The counterclaim by an alleged victim of MIT professor David Sabatini said she was coerced into sex and that Sabatini’s laboratory had a “toxic and sexually charged” environment.

  December 8, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Cancer Diagnostics Company CEO is Stephen Hahn’s Next Act

  At Harbinger, Hahn will oversee the development of the Bio-AI diagnostics platform dubbed HarbingerHx, in hopes of detecting cancer in a patient before it is visible or symptomatic.

  December 8, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Newpath Commits $350 Million to Fund the Next Good Things in the Life Sciences

  Newpath is guided by the ethos: “Do the right thing and good things will happen.”

  December 8, 2021

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Drug Development

  After Setbacks, CymaBay Pushes Forward with Potential Liver Disease Treatment

  The holds were lifted by the FDA in July of 2020, but the company’s timeline had been severely set back by the miscalculation.

  December 8, 2021

   · 

  4 min read

   · 

  Alex Keown
• 

  Policy

  Former Martin Shkreli Company Vyera Settles Federal Lawsuit for $40 Million

  Vyera Pharmaceuticals agreed to pay $40 million to settle federal allegations to radically increase the price of toxoplasmosis drug Daraprim and prevent generic competition.

  December 8, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Life Sciences Expansions Take Off as 2021 Wraps Up

  Several life sciences companies and life science-focused real estate firms have announced expansion plans as 2021 comes to an end.

  December 8, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  With Positive Data in Hand, Neurocrine and Acadia Prepare for NDAs

  Neurocrine Biosciences and Acadia Pharmaceuticals posted positive top-line results from their respective Phase III trials on major neurological diseases.

  December 8, 2021

   · 

  3 min read

   · 

  Vanessa Doctor, RN